“We believe that the Stage 3 rule should be paused as it should rely on proven technology — designed outside the limitations of current federal requirements — that can support a shift to outcomes and interoperability rather than measures and objectives,” the authors wrote.
The letter states that if enacted on schedule in 2017, Stage 3 will only exacerbate the problematic policies of Stage 2 and incentivize technology that emphasizes arbitrary measurements of provider performance, rather than interoperability and improved health outcomes.
“While healthcare providers are committed to implementing EHRs, many are becoming disenchanted by the seemingly unrealistic expectations dictated by the Meaningful Use program,” the authors wrote. “Taking the time to get it right now will surely pay dividends in the future.”
More articles on health IT:
Facing an EHR update? Here are 5 steps for success
80% of info security experts experience data leakage: 6 things to know
19 expert health IT tips for successful implementation, optimization
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
